Not checked for notices yet.
The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE−/− and LDLr−/− Mice by a Mechanism That Includes Inflammatory Pathways
Günaj Rakipovski, PhD, Bidda Rolin, DVM, Jane Nøhr, PhD and 7 more (opens in a new tab)
JACC: Basic to Translational Science · 2018
doi:10.1016/j.jacbts.2018.09.004 (opens in a new tab)
Cited by papers we hold 7
- Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists · 2024No notice
- Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent · 2023No notice
- GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives · 2023No notice
- Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials · 2021No notice
- GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects · 2021No notice
- GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential · 2021No notice
- The Discovery and Development of Liraglutide and Semaglutide · 2019No notice
Questions about this paper
We email you if it is retracted, withdrawn, corrected or flagged.
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.